SG Americas Securities LLC Acquires New Position in LifeMD, Inc. (NASDAQ:LFMD)

SG Americas Securities LLC bought a new position in LifeMD, Inc. (NASDAQ:LFMD) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,279 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors also recently modified their holdings of the company. ClariVest Asset Management LLC grew its stake in LifeMD by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock valued at $631,000 after purchasing an additional 2,600 shares in the last quarter. Quest Partners LLC bought a new stake in shares of LifeMD in the 2nd quarter valued at approximately $31,000. Deerfield Management Company L.P. Series C grew its stake in shares of LifeMD by 25.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 40,289 shares of the company’s stock valued at $276,000 after buying an additional 8,204 shares in the last quarter. EntryPoint Capital LLC acquired a new position in LifeMD in the first quarter worth approximately $89,000. Finally, Los Angeles Capital Management LLC bought a new position in LifeMD during the second quarter valued at approximately $88,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Stock Performance

NASDAQ:LFMD opened at $4.40 on Tuesday. The firm has a market capitalization of $183.52 million, a PE ratio of -5.94 and a beta of 1.18. LifeMD, Inc. has a 1 year low of $4.10 and a 1 year high of $12.88. The company has a current ratio of 0.87, a quick ratio of 0.83 and a debt-to-equity ratio of 10.83. The firm’s fifty day simple moving average is $4.93 and its 200 day simple moving average is $6.87.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. On average, sell-side analysts anticipate that LifeMD, Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

LFMD has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th. KeyCorp lowered their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, B. Riley began coverage on LifeMD in a report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.